Incidence of thromboembolic events in testicular cancer patients receiving cisplatin (TESTCIS study).

= 0.01124) had a statistically significant relationship with the occurrence of a thromboembolic event. The chemotherapy regimen was changed for three patients (5.4%) due to a thromboembolic event. Overall, 7 out of 56 patients (12.5%) received thromboprophylaxis, and three of these patients nevertheless experienced a thromboembolic event. Five patients (8.9%) experienced bleeding, but only one of these five patients (who was not on anticoagulant therapy) experienced a major bleed.ConclusionThe observed occurrence of thromboembolic events in 41.1% of patients in the TESTCIS study illustrates a need for further studies and discussions to identify true benefits of thromboprophylaxis for patients with testicular cancer receiving a cisplatin-based protocol. Based on our observations, we believe that recurrent testicular cancer and a Khorana score of 2 or more at initial assessment should be considered exploratory findings that warrant confirmation in larger prospective studies. Careful attention should also be paid to patients with superficial venous thrombosis, as this condition may put the patient at risk of a subsequent major thromboembolic event. The efficacy and safety of thromboprophylaxis in this patient population should be evaluated further in a post-intervention study.